GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing